CLINICAL REPORT
ALLOGENIC MESENCHYMAL STEM CELL THERAPY FOR IMMUNE MEDIATED CYTOPENIAS – A 22 CASE SERIES STEVEN D. GARNER, DVM, DABVP CHIEF OF STAFF SAFARI VETERINARY CARE CENTERS LEAGUE CITY, TEXAS DOCGARNER@SAFARIVET.COM
ABSTRACT Immune mediated cytopenias (IMCP) are common disease syndromes in veterinary practice (1) (2). It is one of the many diseases caused by autoantibodies that respond to mesenchymal stem cell therapy (3). Blood transfusions along with corticosteroids and other antimetabolites such as azathioprine, cyclosporine, meclofenoxate and leflunomide are the foundation of current therapy for immune mediated hemolytic anemia (3) (4). This current therapy is deemed effective as a cure in only about 1/3 of the cases, while another 1/3 of the cases become symptom free as long as immunosuppressive medications are given and the final 1/3 of the cases die from the effects of rapid uncontrollable hemolysis (2) (4). Mesenchymal stem cells represent great promise for the treatment of immune-related diseases due to their potent immunomodulatory properties (5). Twenty-two clinical cases of immune mediated cytopenia are described that have been treated with allogenic mesenchymal stem cells (AMSC) in addition to traditional therapy or as the only therapy. Of these 22 cases, 17 cases showed a positive response demonstrating the potential value of AMSC in modulating immune mediated cytopenia in the dog.
RESULTS These are ongoing clinical cases occurring over a period of 20 monthsa. Of the 22 cases 20 are immune mediated hemolytic anemia (IMHA) and 2 are immune mediated thrombocytopenia (ITP). Treatment of the 22 cases with intravenous infusion of AMSC’s resulted in 17 cases which demonstrated clinical improvement as documented by rising cell counts, improved clinical signs and reduction of immunosuppressive therapies and 5 cases that did not respond. 12 of 13 of the regenerative IMHA/ITP cases responded and 5 of 9 of the nonregenerative IMHA/ITP cases responded. Of the 17 responding cases, 12 were complete responses where the PCV and cell counts returned to normal values with or without additional immunosuppressive therapy and 5 of the 17 cases the pet returned to clinical normalcy with elevated cell counts, but the cell counts remained below normal. 2 cases of the 5 that did not respond had unresponsive bone marrow failure and the other 3 cases had poor response to or inadequate application of the stem cell therapyb. One of these 5 dogs died and the other 4 a
These cases are subject to the clinical decisions made by the clients and the referring veterinarians. Every effort has been made to obtain and report accurate medical records from these cases, however, some of the medical records are incomplete. Some of the cases are still being evaluated. b Euthanasia decisions were made by the client and often were made just as the stem cell therapy was initiated. In general, stem cell therapy that was deemed inadequately applied was applied too late in the course of the disease.
were euthanized. One of these cases had a mild adverse reaction to the stem cell therapy. Of the 9 IMHA nonregenerative anemia cases, 5 responded to stem cell therapy and 4 died or were euthanized. Of the 2 Evans disease cases, one died and one responded to stem cell therapy. Both cases of ITP responded to stem cell therapy as evidenced by removal of immunosuppressive therapy and stabilization of platelet counts. Immune mediated cytopenia therapy can be successfully augmented by the addition of AMSC in a high percentage of cases. See Table #1
TABLE #1 RESULTS C O N D IT IO N IM H A (R E G E N E R A T IV E ) IM H A (N O N -R E G E N E R A T IV E ) TOTAL
NUMBER
13 9 22
T O T A L IM P R O V E D
12 5 17
INTRODUCTION Immune mediated cytopenia is a disease that is commonly described as the overproduction of autoantibodies to cellular antigens causing the premature destruction or removal of the cellular elements of blood. Immune mediated cytopenia includes disease of the peripheral blood such as immune mediated hemolytic anemia (IMHA), immune mediated thrombocytopenia (ITP) and the combination of these two diseases or Evans syndrome c. These diseases can be regenerative with normal bone marrow function or non-regenerative where the progenitor cells within the bone marrow are affected as well. Traditional therapy involves blood transfusions as needed to maintain homeostasis while immunosuppressive medications are used to halt the anti-blood cell antibody production and suppress the reticuloendothelial system (1) (3). Current therapy, therefore, has been directed at reducing the antibody production using antimetabolite drugs that are aimed at the B-lymphocytes and their plasma cell clones. Immunosuppressive drug regimens, however, have a high incidence of adverse effects such as diabetes, Cushing’s disease, gastrointestinal ulceration, secondary infections and clinical ineffectiveness driving the need for alternative therapies (6) (7) (8) (9). Anti-blood cell antibody production is ultimately the result of the breakdown of central and or peripheral immune tolerance mechanisms (5) (10). These diseases result from a failure in the body’s ability to differentiate between cells from the body and foreign cells. Immune tolerance is mediated through a subset of T-lymphocytes with immune regulatory cytokine secretion (Treg cells) (11) (12) (13). Allogenic mesenchymal stem cell therapy has been documented as having anti-inflammatory properties (14) (15) (16), to mediate autoimmune disease (17), and stimulate the production of Treg cells in the presence of inflammation (18) (19) . Mesenchymal stem cell therapy has been shown to both cancel the effects of the autoantibodies and to correct the errors in the immune tolerance mechanisms that mis-program the B-cells in the first place (5). Stem cells also produce Factor H which is the primary regulator of complement (11) (12) (13). Stem cell therapy seems to be an effective tool in stopping the immune destruction in immune mediated cytopenias. Allogenic mesenchymal stem cells are non-immunogenic, easily accessible, can be expanded to clinical scales in a short period of time, and can be biopreserved and shipped for point-of care delivery to the pet with minimal loss of potency enabling these donor cells to be used in clinical cases that are too sick or too time sensitive for autologous fat processing.
c
Immune mediated neutropenia is another immune mediated cytopenia that has been treated by the author with AMSC but is not a part of this report as results are not yet available.
OVERVIEW IMMUNE MEDIATED CYTOPENIAS IN DOGS The bone marrow is the source of red blood cells, white blood cells and platelets. These cells come from the hematopoietic stem cell. Hematopoietic stem cells create the three lines of cells that form all three of the cellular blood components (white, red and platelets). Hematopoietic stem cells within the central marrow of the bones reside in a loose spongy matrix. The matrix is composed of calcified bony spicules which house osteoblasts and osteoclasts, fibroblasts, reticular cells, and adipose cells as well as bone marrow stromal cells (BMSC). These bone marrow stromal cells are stem cells and are essential in producing the chemical stimulus for hematopoietic stem cells to form the blood cells. Therefore, two essential stem cells lines are present in the bone marrow,: one that produces the blood cells (hematopoietic) and another that provides the chemical instructions for this production (BMSC). The hematopoietic stem cell produces daughter stem cells that become the source of the individual cell lines. The red cell line source is the erythroblast, the white cell lines come from the myeloblast, lymphoblast and monoblast and the platelet cell line source cell is the megakaryocyte. Immune-mediated hemolytic anemia (IMHA) is caused when antibodies are produced against the red blood cell antigens. This causes the red blood cell to be destroyed either within the blood stream (intravascular hemolysis) or within the spleen (extravascular hemolysis). This red cell destruction results in anemia which should stimulate the bone marrow to produce more red blood cells. This regenerative response is measured by identifying reticulocytes in the circulation. When there are not adequate numbers of red blood cells in the circulation it is called non-regenerative anemia (NRA). NRA occurs because the erythroblast has also been targeted in the immune attack. In some cases, the bone marrow failure is due to exhaustion of the erythroblast cells or lack of raw materials such as iron. In human medicine, a similar disease called aplastic anemia (AA) occurs where there is an immune attack on the hematopoietic stem cell itself so that all cell lines are affected and the person has low red blood cells, low white blood cells and low platelets as well. In these cases, human patients are usually given a bone marrow transplant or a hematopoietic stem cell transplant. This transplant must be given from a sibling donor or a suitable unrelated donor with matching tissue type. Pure Red Cell Aplasia (PRA) is an infrequent hematologic complication from hematopoietic stem cell transplantation when the transplanted cells are mismatched with the recipient. Allogenic mesenchymal stem cells have also demonstrated efficacy in the treatment of refractory PRA in humans (20) (21). Immune mediate thrombocytopenia (ITP) is characterized by immune-mediated destruction of normal platelets and suppression of platelet production that is associated with variable bleeding syndromes (22). The underlying immune dysregulation results in antiplatelet antibodies directed at the platelet and megakaryocyte surface glycoproteins. These antiplatelet antibodies develop secondary to a loss of tolerance to these surface-antigens of the platelets and megakaryocytes (23). Recently it has been demonstrated that mesenchymal stem cells (MSC) from adipose tissue can support the hematopoietic matrix within the bone marrow (24). MSC transfusions have been shown to cure AA patients through the stimulation of the production of a new hematopoietic matrix. Allogenic Mesenchymal Stem Cell (AMSC) therapy can be used to improve the chances of recovery from these diseases through three paths: immunomodulation, increased hematopoiesis and the promotion of immune tolerance (25) (26). IMMUNE TOLERANCE There are natural balances in the controls of the immune system that we are just coming to understand. These balances involve the production of different types of T-Lymphocytes (T-cells) depending on the need for immunity
vs. tolerance. Immune tolerance is the need to tolerate the presence of a seemingly abnormal protein or substance. For example, our intestine houses many species of bacteria that are arguably foreign to our bodies, yet our immune system tolerates their presence. Mammals who maintain placental pregnancy within their bodies must tolerate the foreign tissue of the developing fetus with different DNA than the mother and not attack it as foreign. The surface of the skin and opening of the mucous membranes harbor “normal” bacterial and fungal flora that must be tolerated by the immune system. On the other hand, cells that are infected or damaged or that have turned cancerous should be attacked and removed from the body by the same immune system. It is this balance that is defective with IMCP. Recent experiments involving the thymus gland have uncovered previously unknown elements of the T-cell populations that help control these systems. Mutant mice which do not have a thymus gland spontaneously develop fatal, widespread, early-onset autoimmunity (27). Removal of the thymus gland in three-day old mice led to the rapid development of autoimmunity that was corrected by the infusion of T-cells from adult mice. This research advanced our understanding of the creation and management of the T-cell lineage and how it controls the immune system. Certain T-cell types regulate or keep in check the aberrant or overactive activity of other Tcells. When functioning normally, the immune system produces a population of T-cells that have regulatory function (Tregs) that are specialized for immune suppression (18). In addition, it is becoming apparent that every immune reaction not only creates specific B-Cells and T-Cells but also Tregs and the balance between the different populations of cells is critical for the proper control of the immune response. IMHA is an example of an excessive attack on self-antigens as a result of improper immune tolerance resulting from dysregulation or deficiency of the Tregs (28) (18). ALLOGENIC MESENCHYMAL STEM CELL THERAPY Allogenic mesenchymal stem cell therapy is the intravenous use of adipose derived stem cells from the same species. In intravascular IMHA where red blood cells are destroyed by complement activation (3), stem cells block complement attacks by secreting Factor H (29) (30) (31) (32). Stem cells promote the creation of Treg cells by production of transforming growth factor beta (TGF-β) (19) (27) (32). Stem cells down-regulate the production of antibodies by B-cells and down-regulate macrophage consumption of red blood cells. The stem cells’ response is modulated by the relative need and will not affect the rest of the immune system’s ability to fight disease. AMSC’s are not allergenic or recognized by the immune system (33) (34). They have been shown safe when given intravenously in numerous human Phase I and Phase II Clinical Trials (35) (36) (19). More general research has shown that stem cells possess anti-inflammatory and immunomodulatory properties; primarily by modulating the type and function of T-Lymphocytes (14) (15) (37) (16) (38) (39) (17) (40) (41) (42). There is a large body of research demonstrating the importance of subsets of T-cells in preventing disease. TH1 cells produce Interferon (IFN)-γ which stimulates cell mediated immunity against tumor cells, intracellular bacterial or viral infected cells. In contrast TH2 cells produce many cytokines including interleukin (IL)-4, IL-5, IL-9 and IL-13 which activate B-cells allowing them to transform into the plasma cell clones that produce antibodies. More recently, other subsets of cells such as the TH17 cells have been shown to play a role in the battle against infectious agents at mucosal barriers. And TH9 cells that are responsible for the response against helminths. These cells do not act, however, until they receive their orders in the form of chemical messages (cytokines). The cytokines tell the cells who to attack and with what weapons. Stem cells produce the cytokines that determine the type of T-cell and the “orders” for the action of these T-cells based on the needs of the animal. Stem cells, unlike conventional therapeutics, are alive and dynamically self-modulate the secretion of bioactive factors and signals at variable concentrations in response to local micro-environmental cues and actually offer a cure for IMCP’s as they reprogram the immune tolerance of the animal (19).
CASE DISCUSSION Immune mediated cytopenias respond rapidly to the intravenous infusion of allogenic mesenchymal stem cells. Early administration of stem cells while there is a robust regenerative response is rewarded with the best clinical outcomes. Many of the cases in this report however are severe cases where stem cell therapy is the last resort only tried when all other therapies have failed. Even in these severe cases, however, stem cell therapy has demonstrated effectiveness. For example, some IMHA cases have very aggressive red blood cell destruction requiring more than one transfusion per day and this cycle can be stopped abruptly by the infusion of AMSC. See cases #15, #16 and #17 along these lines. Of the 9 non-regenerative anemia cases only 5 responded while 12 of 13 regenerative anemia cases responded to stem cell therapy. Some cases were not as successful because of poor timing of the stem cell therapy or because of abject failure of the bone marrow to respond to the stem cells as evidenced in cases #10 and #18. The therapeutic objective in some cases was not to increase the cell count but to reduce the immunosuppressive drugs. This is especially true with the two cases of ITP (Case #21 and #22) that were in remission but still on prednisolone that was weaned with the aid of stem cells. Finally, many pets in this series had concurrent disease such as vasculitis, dermatitis, transfusion related lung injury (TRALI), thromboembolism and seizure disorders that resolved after the stem cell therapy. See Table #2.
Table #2 Clinical Case Details Signalment CASE #1 Non-Regenerative 13-year-old Dachshund with IMHA Nonregenerative. Diagnosed 3.5 months prior to stem cell therapy.
CASE #2 3.4-year-old dachshund/schnauzer mix that was referred for severe anemia over the past two weeks that had not responded to a steroid injection at referring vet.
CASE #3
Charted PCV and Treatments
Comments Reticulocytes counts at 7.5K are low. Non-regenerative anemia. Each transfusion lasts about 28 days. More cells may stimulate marrow production. Pet is clinically normal. Responded Clinically
The Pet Owner mentioned: “His skin condition cleared up too”. It is not unusual to see an “overswing” in PCV then a settling as is demonstrated in this pet. This pet is not on immunosuppressive therapy. Responded Completely
Responded Completely
3-year-old intact female Dachshund. She has had 3 transfusions before considering stem cell therapy.
CASE #4 Non-regenerative 15-year-old female Papillion which for two days she has been anorexic, has been having diarrhea, is very weak, and Pu/PD. Presumptive diagnosis is IMHA. She does not have adequate reticulocytes.
Her blood tests show high liver and kidney values. She was only mildly anemic but was hospitalized and given IV fluids. The next day she became very anemic, was given a blood transfusion and stem cells two days later. Her reticulocyte counts began at 2k and 10.7K after stem cells they went up to about 30K. Responded Clinically
CASE #5 Non-Regenerative
Stem cells were given three weeks later and again 6 weeks later. Responded Completely
10-years-old male dachshund/pit-bull mix that presented as a referral for anemia. Blood was given at the referral hospital.
CASE #6 4-year-old American Bulldog with IMHA diagnosed in March of 2018. The pet has a rash on its belly and his ear flaps are swollen, he is lethargic, anorexic, and has not needed any transfusions to date. One digit is swollen and is thought to have pythium. The pet has also been diagnosed with Bartonella.
CASE #7 6-month-old Male Labrador Retriever with IMHA. The pet also has edema in the legs, and pneumonia as well as skin lesions,
Pet is on Atopica and Mycophenolate, prednisone and Plavix. The pet had rare spherocytes noted after pathologist review but overall, his CBC suggests that his IMHA is in remission after the stem cells. Responded Completely
After the first round of stem cells the owner reports:” the pet has crazy amount of energy. pneumonia looking better, skin lesions clearing up, next to no swelling especially in the hock.” The pet is currently on prednisolone. Responded Clinically
CASE #8 5-year-old Male dachshund mix with IMHA and a history of seizures. This pet has severe anemia and has had four transfusions and IVIG that has not stopped the cell destruction.
The pet owner reports: “the pet has lots of energy, good mood, good appetite. There are tremors in hind legs. He has not had any seizures since his stem cells.” Splenectomy was performed at the referral center just after stem cells given. Responded Completely
CASE #9 Non-Regenerative 8-year-old male whippet with severe IMHA. The PCV was 14% which dropped to 12% before the first dose of stem cells arrived.
Pet's lungs filled with fluid later the 4th night after the cells and the owners opted to euthanize. This pet likely had thromboembolism and was likely affected by rapid onset of intravascular hemolysis. Blood transfusions may have stabilized the pet long enough for the stem cells to be effective. Maybe add a synopsis statement?
CASE #10 3.5-year-old goldendoodle. This pet has had severe IMHA that has been managed with seven blood transfusions over the previous month as well as two doses of IVIG.
CASE # 11 Non-Regenerative 12-year-old beagle with IMHA who had her spleen removed in 2018 due to a benign mass. She has had IMHA for a month and had a transfusion one month ago. Since then she was treated with stem cells only. Two doses 6 days apart and another dose the next week and a final dose two months later.
CASE # 12 Non-Regenerative 3.5-year-old female spayed terrier mix which presented with a PCV of 17. IMHA suspected. The pet was put on prednisolone for one month. One round of stem cells put the PCV back into the normal range.
The pet was on prednisone, cyclosporine and leflunomide. Only one dose of cells was given. Pet had vasculitis, swollen legs and anorexia before cells were given. The cells were given late in the disease course and toward the end of the client’s ability to treat the pet. Euthanasia was elected.
A blood smear one month after the stem cells showed no spherocytes, no mega platelets few target cells. These results indicated the immune destruction of the cells is now stopped but there may be an iron deficiency. Responded Clinically
Responded Clinically
CASE #13 EVANS 11-year-old male dachshund with both IMHA and ITP. (Evans Syndrome) for the past three months that has been difficult to manage. The pet’s PVC was at 20% when cells were called for. A blood transfusion raised the PCV to 30%.
CASE #14 Non-Regenerative 11.5-year-old male dachshund with severe IMHA. Five transfusions were given in the two weeks prior to stem cell therapy. The last transfusion was given the day before the stem cells were given. An additional cell therapy was sent but not given. CASE #15 2-year-old, female spayed Shih Tzu who has severe IMHA. She was in the ICU for 10 days during which she received 7 blood transfusions.
The first dose of cells was given 5 days after the transfusion. The second dose of stem cells was attempted three days later. The pet had an adverse reaction. He started drooling, got very white, became weak and his hind legs gave out, his heart was racing. The referring vet gave him Benadryl to which he responded, he “pinked” up and had his strength back. Since he had the reaction and was otherwise not responding the owner elected euthanasia.
The pet collapsed at home with a PCV of 8% and was euthanized. Add “euthanized” to the graph like the one above
She started out on prednisone, added mycophenolate day 3, Atopica day 7. Now she is doing well just on 5mg prednisone once every 3 days. Also, melatonin 3mg, salmon oil, and Plavix once daily and all blood values are normal. Responded Completely
CASE #16a&b Pre-Regenerative 8-year-old male Jack Russel Terrier with severe IMHA. This pet had 6 transfusions in 4 days as well as Therapeutic plasma exchange (TPE) or plasmapheresis. Two doses of stem cells at 2x106 cells/Kg were given one day apart followed by a third dose one week later.
TRALI (Transfusion Related Lung Injury) event after TPE. The lung issues resolved after the stem cell therapy.
The pet was in complete remission of the IMHA for 3 months then relapsed.
The relapse was thought by the client to have correlated with the abrupt discontinuance of azathioprine. Two transfusions and 4 stem cell rounds were effective. The pet is now normal 6 months after the relapse. Responded Completely
CASE #17 8-year-old female Rat Terrier with a one-week history of IMHA. She also has a seizure problem.
This pet was treated with blood and cells in a rapid fashion resulting in a rapid reversal of the IMHA. In addition, she has not had a seizure since the stem cells were given. Responded Completely
CASE #18 Non-Regenerative 8-year-old female dachshund with nonregenerative anemia or red blood cell aplasia. It has not had a bone marrow biopsy. Stem cells were given 5 times.
The stem cells did not restart the production of red blood cells, but the stem cells did increase the life of the transfused cells. She was on prednisolone the entire time. The pet did however develop an infection and had high glucose and elevated WBC. She was given Baytril and was to begin weaning off her prednisone the next day, when she took a turn for the worse. Owner opted to euthanize. Aplastic Anemia or Bone Marrow Failure
CASE #19 EVANS 2-year-old male neuter ed Boston Terrier with IMHA and ITP. He was given two blood transfusions and IVIG therapy 7 months prior to giving stem cell therapy.
Today (18 months later) there are no spherocytes and 53% PCV. He is on Atopica and prednisolone both lowered. Responded Completely
CASE #20 10.6-year-old male neutered mix breed dog with IMHA. He presented with white gums, was very lethargic and given a blood transfusion.
Case #21 – ITP 2 year old MN Chihuahua mix. Diagnosed two months prior with ITP. Previous Vet recommendations were to leave on prednisolone for life. Owner was not content with the prognosis that it always reoccurs.
Case #22 – 4 Year old FS maltipoo diagnosed with ITP two years ago. Recently relapsed but responded to immunosuppressive therapies. The pet does not tolerate the drug protocol. Wants stem cells to wean off medications.
Two rounds of stem cells placed him on a stable PCV of about 30%. He is clinically normal but his PCV is still lower than the normal value. Additional cells should help this situation. Responded Clinically
He has had one round of cells and has reduced his prednisone by half and is waiting another round of stem cells before completely stopping the medications. Responded Completely
Two doses of cells given 30 days apart with discontinuation of the immunosuppressive medications. Close monitoring is continuing. Responded Completely
MATERIALS AND METHODS Allogenic mesenchymal stem cells are sourced from canine donors’ adipose tissues. The cells are processed, cultured and expanded following protocols described elsewhere. The cells are from a single donor and are “fresh” cells in that they come from actively growing cultures of less than 5 generations or passages. These cells are not reconstituted cryopreserved cells. Heparin is added to the culture medium (4U/ml) 12 hours prior to harvest to enhance therapeutic effectiveness and reduce the first pass effect (43) (44). The cells are then washed with PBS twice to remove residual heparin. Alternatively, the pet may be pretreated with heparin (200U/kg). The cells are then harvested from their cultures, counted with an automated cell counter, tested for viability and placed in a single use vial for the specific pet. The cells are dosed at 1 million cells per kg. Overnight shipping to the point of-care facility results in minimal loss of potency, enabling these donor cells to be used in clinical cases that are too sick or too time sensitive for autologous fat processing. They are then diluted and administered intravenously over a 30-minute time period.
CONCLUSION Stem cell therapy in the treatment of IMHA offers therapeutic advantages focused at the root of the IMHA disease. Research has shown that stem cells possess anti-inflammatory and immunomodulatory properties, primarily by modulating the type and function of T-Lymphocytes (14) (15) (37) (16) (38) (39) (40) (41) (42). In addition complement activation and subsequent hemolysis is a major factor in IMHA mortality (2) (15) (14) (4) and is the mechanism for the rapid destruction of the transfused cells. Mesenchymal stem cells constitutively produce Factor H which is the primary regulator of complement activation. Factor H production from intravenous stem cell infusions effectively shuts down intravascular hemolysis secondary to complement activation thereby potenitially saving the lives of the pets affected by this form of IMHA (45; 46). Stopping production of the billions of anti-red blood cell antibodies produced per second is strategic for winning the battle in IMHA. Immunosuppressive drugs are the traditional linchpin functioning as anti-metabolites against antibody producing lymphocytes. Stem cells augment this strategy by producing Treg cells that produce a variety of cytokines that have the ability to kill antibody producing cells, effectively stopping the anti-red blood cell IgG antibody production responsible for the extravascular hemolysis (spherocytes) noted in Case #11 and case #19 of this report (47) (28). The processing of red cell surface proteins as “not-self” by macrophages and dendritic cells in the reticuloendothelial system is the underlying origin for anti-red blood cell antibody production in IMHA. Stem cells make Treg cells by producing the soluble protein Transforming Growth Factor Beta (TGF-β) (48) (49). TFG-β converts T-lymphocytes to Treg lymphocytes and Treg cells have the ability to direct the macrophages and dendritic cells to once again recognize the red blood cell antigens as “self” and not foreign (50) (28). In fact, these Treg cells also produce memory Treg cells that remember that the red cell antigens are “self” in the future, effectively having the potential to cure IMHA. Allogenic MSC are anti-inflammatory, immunomodulatory and regenerative. Intravenous infusion of these cells has been shown to be a safe way to decrease the antibody induced destruction of cells while increasing the production of red blood cells and platelets in animals suffering from various types of immune mediated cell and bone marrow damage. The therapeutic effect of stem cells on IMHA needs further evaluation for dose of cells, timing of administration and when to discontinue therapy.
COMPETING INTERESTS The author, Dr. Garner owns and operates the stem cell laboratory at Safari Veterinary Care Centers in League City, Texas. As such he acknowledges a financial interest in stem cells provided for use in the cases in this report.
REFERENCES 1. Canine Immune-Mediated Hemolytic Anemia: Pathophysiology, Clinical Signs, and Diagnosis. Andrea Balch, Andrew Mackin. 2007, compendium. 2. Immune-mediated haemolytic anaemia – a retrospective study – focus on treatment and mortality. ALLYN, M. E. & TROY, G. C. 2007, Journal of Veterinary Internal Medicine, Vol. 11, p. 131. 3. Canine Immune-Mediated Hemolytic Anemia: Treatment and Prognosis. Andrea Balch, DVM, MS, DACVIM,Andrew Mackin, BVMS, DACVIM. s.l. : Compendium, April 2007, Compendium. 4. Idiopathic Immune-Mediated Hemolytic Anemia: Treatment Outcome and Prognostic Factors in 149 Dogs. C.J. Piek, G. Junius, A. Dekker, E. Schrauwen, R.J. Slappendel, and E. Teske. Utrecht, The Netherlands : s.n., 2008, J Vet Intern Med, Vol. 22, pp. 366-373. 5. The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of ImmuneRelated Diseases: A Systematic Review. Alessander Leyendecker Jr., Carla Cristina Gomes Pinheiro, Mariane Tami Amano, Daniela Franco Bueno. Sao Paulo, Brazil : s.n., September 11, 2018, Frontiers in Immunology. 6. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. CREED, T. J., LEE, R. W., NEWCOMB, P. V., DI MAMBRO, A. J., RAJU, M. & DAYAN, C. M. 2009, Journal of Immunology, Vol. 183, pp. 164-171. 7. Biochemical basis for the hypercoagulable state seen in Cushing syndrome. CHASTAIN, C. B. & PANCIERA, D. 2002, Small Animal Clinical Endocrinology, Vol. 12, p. 11. 8. Evaluation of prognostic factors, survival rates, and treatment for immune-mediated haemolytic anaemia in dogs:. WEINKLE, T. K., CENTER, S. A., RANDOLPH, J. F., WARNER, K. L., BARR, S. C. & ERB, H.N. 2005, Journal of the American Veterinary Medical Association, Vol. 226, pp. 1869-1880. 9. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. N. T. Whitley, M.J. Day. s.l. : British Small Animal Veterinary Association, 2011, Journal of Small Animal Practice, Vol. 52, pp. 70-85. 10. New Insights in the Pathogenesis of Autoimmune Hemolytic Anemia. Barcellini, Wilma. Milan, Italy : s.n., September 7, 2015, Transfusion Medicine and Hemotherapy, Vol. 42, pp. 287-293. 11. Immunobiology of mesenchymal stem cells. S Ma, N Xie, W Li, B Yuan, Y Shi*, and Y Wang. s.l. : Macmillan Publishers Limited, 2014, Cell Death and Differentiation, Vol. 21, pp. 216-225. 12. Glucocorticoids in T cell development. ASHWELL, J. D., LU, F. W. & VACCHIO, M. S. 2000, Annual Review of Immunology, Vol. 18, pp. 309-345.
13. Rapid glucocorticoid effects on immune cells. BUTTGEREIT, F. & SCHEFFOLD, A. 2002. 14. Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF. 2005, Transplantation, Vol. 105, pp. 1815–1822. 15. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Iyer S, Rojas M. 2008, Expert Opin Biol Ther, Vol. 8, pp. 569-582. 16. Stem cells and cell therapies in lung biology and lung diseases. Weiss DJ, Bertoncello I, Borok Z, Kim C, Panoskaltsis-Mortari A,Reynolds S et al. 2011, Proc Am Thorac Soc, Vol. 8, pp. 223–272. 17. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. 2008, Cell Stem Cell, Vol. 2, pp. 141-150. 18. Regulatory T Cells and Immune Tolerance. Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura, and Masahiro Ono. Kyoto : Elseiver, 2008, Cell, Vol. 133, pp. 775-787. 19. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Matthew B Murphy, Kathryn Moncivais and Arnold I Caplan. Austin : s.n., July 8, 2013, Experimental & Molecular Medicine, Vol. 45, p. 54. 20. Allogeneic Bone Marrow‐Derived Mesenchymal Stromal Cells Expanded In Vitro for Treatment of Aplastic Anemia: A Multicenter Phase II Trial. Jiang, Yan Pang Hao‐Wen Xiao Hang Zhang Zeng‐Hui Liu Li Li Yang Gao Hong‐Bo Li Zu‐Jun. [ed.] Anthony Atala. 7, Guangzhou : John Wiley & Sons, Ltd, 05 15, 2017, Stem Cells Translational Medicine, Vol. 6, pp. 1569-1575. 2157-6564. 21. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Fang, B., Song, Y., Li, N. et al. September 04, 2009, Ann Hematol. 22. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell– depleting therapy with rituximab. Roberto Stasi, Nichola Cooper, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Elisabetta Abruzzese, Sergio Amadori. 4, Rome, Italy : AmericanSocietyofHematology, 2008, Blood, Vol. 112, pp. 1147-1150. 0006-4971. 23. Despotovic, Jenny M. Immune Hematology - Diagnosis and Management of Autoimmune Cytopenias. Houston : Springer, 2018. 24. Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Norihiko Nakao, Takayuki Nakayama,Takashi Yahata, Yukari Muguruma,Shigeki Saito, Yasuhiko Miyata,Koji Yamamoto, and Tomoki Naoe. 2, Nagoya, Japan : American Society for Investigative Pathology, August 2010, The American Journal of Pathology, Vol. 177. 25. Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic Anemia. Vivian Fonseca Gonzaga, Cristiane Valverde Wenceslau, Gustavo Sabino Lisboa, Eduardo Osório Frare, and Irina Kerkis. Sao Paulo : Hindawi, 12 03, 2017, Stem Cells International. 1687-966X. 26. Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Negi Neema, Griffin Matthew D. Galway,Ireland : John Wiley & Sons, Ltd, 01 29, 2020, Stem Cells Journals. 1066-5099. 27. Regulatory T Cells: Differentiation and Function. Rudensky, George Plitas and Alexander Y. s.l. : American Association for Cancer Research, 2016, Cancer Immunology Research.
28. Novel immunotherapies for immune-mediated haemolytic anaemia in dogs and people. James W Swann, Oliver A Garden. London : Elsevier, October 15, 2016, The Veterinary Journal, Vol. 207, pp. 13-19. 29. The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in MonocyteDerived Dendritic Cells. Rut Olivar, Ana Luque, Sonia Ca ŕ denas-Brito, Mar Naranjo-Go m ́ ez, Anna M. Blom,Francesc E. Borra`s, Santiago Rodriguez de Cordoba, Peter F. Zipfel, and Josep M. Aran. 2016, The Journal of Immunology, Vol. 196, pp. 4274-4290. 30. Mesenchymal Stem Cells Inhibit Complement Activation by Secreting Factor H. Zhidan Tu, Qing Li,Hong Bu,Feng Lin. 11, s.l. : © Mary Ann Liebert, Inc., 2010, STEM CELLS AND DEVELOPMENT, Vol. 19. DOI: 10.1089/scd.2009.0418. 31. Mesenchymal Stem Cells Control Complement C5 Activation by Factor H In Lupus Nephritis. Haijun Ma, Chang Liu, Bingyu Shi, Zhuoya Zhang, Ruihai Feng, Minghao Guo, Liwei Lu, Songtao Shi, Xang Gao, Wanjun Chen, Lingyun Sun. s.l. : Elsiever, 2018, EBioMedicine, Vol. 32, pp. 21-30. 32. Mesenchymal stromal cells and the innate immune response. Katarina Le Blanc, Lindsay C. Davies. s.l. : Elsevier, 2015, Immunology Letters, pp. 140-146. 33. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. K. Le Blanc, L. Tammik, B. Sundberg, S. E. Haynesworth, and O. Ringden. 01, s.l. : John Wiley & Sons, Ltd, 2003, Scandinavian Journal of Immunology, Vol. 51, pp. 11-20. 0300-9475. 34. Immunoregulation by Mesenchymal Stem Cells:Biological Aspects and Clinical Applications. Marta E. CastroManrreza, Juan J.Montesinos. [ed.] Marco Antonio Velasco-Vel´azquez. s.l. : Hindawi Publishing Corporation, 2015, Journal of Immunology Research, p. 20. 35. Key aspects of the mesenchymal stem cells (MSCs) in tissue engineering for in vitro skeletal muscle regeneration. Chaudhuri B, Pramanik K. 2012, Biotechnol Mol Biol Rev, Vol. 7, pp. 5-15. 36. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F,Krause D et al. 2006, Cytotherapy, Vol. 8, pp. 315-317. 37. Uccelli A, Moretta L, Pistoia V. Uccelli A, Moretta L, Pistoia V. 2008, Nat Rev Immunol, Vol. 8, pp. 726–736. 38. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. 2009, Blood, Vol. 113, pp. 6576–6583. 39. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4þCD25highFOXP3þ regulatory T cells. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. 2008, Stem Cells, Vol. 26, pp. 212–222. 40. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Yi T, Song SU. 2012, Arch Pharm Res, Vol. 35, pp. 213–221. 41. The chemokine system in diverse forms of macrophage activation and polarization. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004, Trends Immunol, Vol. 25, pp. 677–686.
42. Mesenchymal stem cells as therapeutics. Parekkadan B, Milwid JM. 2010, Annual Review Biomed Eng, Vol. 70, pp. 325–330. 43. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI,. 2009, Stem cells and Development, Vol. 18, pp. 683-692. 44. Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derrived mesenchymal stem cell cytotherapy. Li Liao, Bingzheng Shi, Heran Chang, Xiaoxia Su, Lichao Zhang, Chunsheng Bi, Yi Shuai,Xiaoyan Du, Zhihong Deng, Yan Jin. 1, s.l. : IVYSPRING, 2017, Theranostics, Vol. 7, pp. 106-116. 45. Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis. Haijun Ma, Chang Liu,Bingyu Shi,Zhuoya Zhang,Ruihai Feng,Minghao Guo,Liwei Lu,Songtao Shi,Xiang Gao,Wanjun Chen,Lingyun Sun. 32, s.l. : Elsevier, 2018, EBioMedicine, pp. 21–30. 46. Complement factor H and the hemolytic uremic syndrome. John P. Atkinson, Timothy H.J. Goodship. s.l. : The Rockefeller University Press, June 11, 2007, Journal of Experimental Medicine, pp. 1245-1248. 47. DAY, M. J. & MACKIN, A. J. (2008). Immune-mediated haematological disease. In Clinical Immunology of the Dog and Cat. 2nd. Edn. London, UK : Manson Publishing, 2008. pp. 94-121. 48. Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment. Lukáš Zachar, Darina Bačenková,Ján Rosocha. [ed.] University Hospital of L. Pasteur. Košice, Slovak Republic : Dove Press , 12 15, 2016, Journal of Inflammation Research, Vol. 9, pp. 231-240. 49. Secretion of immunoregulatory cytokines by mesenchymal stem cells. Dobroslav Kyurkchiev, Ivan Bochev, Ekaterina Ivanova-Todorova, Milena Mourdjeva, Tsvetelina Oreshkova, Kalina Belemezova, Stanimir Kyurkchiev. 5, s.l. : Baishideng Publishing Group Inc., World J Stem Cells, Vol. 6, pp. 552-570. 1948-0210. 50. Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T cells by TGF-B Induction of Transcription Factor Foxp3. WanJun Chen, Wenwen Jin, Neil Hardegen, Ke-jian Lei, Li Li, Nancy Marinos, George McGrady, and Sharon M. Wahl. 2003, The Journal of Experimental Medicine, Vol. 198 Number 12, pp. 1875–1886.